Preservation of Biochemical Liver Function With Low‐Dose Soy‐Based Lipids in Children With Intestinal Failure–Associated Liver Disease
- 1 March 2015
- journal article
- research article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 60 (3), 375-377
- https://doi.org/10.1097/mpg.0000000000000609
Abstract
Objectives: Intestinal failure–associated liver disease (IFALD) contributes to significant morbidity in pediatric patients with intestinal failure (IF); however, the use of parenteral nutrition (PN) with a fish oil–based intravenous (IV) emulsion (FO) has been associated with biochemical reversal of cholestasis and improved outcomes. Unfortunately, FO increases the complexity of care: because it can be administered only under Food and Drug Administration compassionate use protocols requiring special monitoring, it is not available as a 3-in-1 solution and is more expensive than comparable soy-based IV lipid emulsion (SO). Because of these pragmatic constraints, a series of patient families were switched to low-dose (1 g kg−1 day−1) SO following biochemical resolution of cholestasis. The present study examines whether reversal of cholestasis and somatic growth are maintained following this transition. Methods: The present study is a chart review of all children with IFALD who switched from FO to SO following resolution of cholestasis. Variables are presented as medians (interquartile ranges). Comparisons were performed using the Wilcoxon signed-rank test. Results: Seven patients ages 25.9 (16.2–43.2) months were transitioned to SO following reversal of cholestasis using FO. At a median follow-up of 13.9 (4.3–50.1) months, there were no significant differences between pretransition and post-transition serum alanine and aspartate aminotransferases, direct bilirubin, and weight-for-age z scores. Because of recurrence of cholestasis, 1 patient was restarted on FO after 4 months on SO. Conclusions: Biochemical reversal of IFALD and growth were preserved after transition from FO to SO in 6 of 7 (86%) patients. Given the challenges associated with the use of FO, SO may be a viable alternative in select patients with home PN.Funding Information
- National Institute of Child Health and Human Development (5K24HD058795)
This publication has 25 references indexed in Scilit:
- Aspartate Aminotransferase to Platelet Ratio Index Correlates With Hepatic Cirrhosis but Not With Fibrosis in Pediatric Patients With Intestinal FailureJournal of Pediatric Gastroenterology and Nutrition, 2013
- Exome sequencing identifies mutations in the geneTTC7Ain French-Canadian cases with hereditary multiple intestinal atresiaJournal of Medical Genetics, 2013
- Prevention and Treatment of Intestinal Failure-Associated Liver Disease in ChildrenSeminars in Liver Disease, 2012
- Parenteral Fish Oil as Monotherapy Prevents Essential Fatty Acid Deficiency in Parenteral Nutrition–dependent PatientsJournal of Pediatric Gastroenterology and Nutrition, 2010
- Parenteral Fish Oil Improves Outcomes in Patients With Parenteral Nutrition-Associated Liver InjuryAnnals of Surgery, 2009
- Safety and Efficacy of a Fish-Oil–Based Fat Emulsion in the Treatment of Parenteral Nutrition–Associated Liver DiseasePEDIATRICS, 2008
- Improved survival in a multidisciplinary short bowel syndrome programJournal of Pediatric Surgery, 2008
- Neonatal short bowel syndrome outcomes after the establishment of the first Canadian multidisciplinary intestinal rehabilitation program: preliminary experienceJournal of Pediatric Surgery, 2007
- The role of enteral nutrition in the reversal of parenteral nutrition–associated liver dysfunction in infantsJournal of Pediatric Surgery, 2005
- Total parenteral nutritionThe Journal of Pediatrics, 1971